A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (CheckMate 370: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 370)
A study for patients with advanced Non small cell lung cancer using study drug Nivolumab
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAQ8181
U.S. Govt. ID: NCT02574078
Contact: Catherine Shu: 212-305-3997 / cas2145@cumc.columbia.edu
Additional Study Information: The purpose of this master study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) alone or in combination with standard of care therapies.
This study is closed
Investigator
Catherine Shu, MD
Do You Qualify?
Have you been diagnosed with Non-Small-Cell Lung Cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Catherine Shu
cas2145@cumc.columbia.edu
212-305-3997
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE